Skip to main content
    G

    Ginkgo Bioworks Holdings (DNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $8.31
    -0.19 (-2.18%)

    Market Cap: $622.97M

    Last updated: Nov 17, 2026 at 4:37 PM ET

    Ginkgo Bioworks Holdings (DNA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Ginkgo Bioworks Holdings (DNA) has a market cap of $622.97M and an enterprise value of $538.46M. It kept -249.20% of revenue as net income over the last 12 months. Its share count is up 14.98% from a year earlier.

    Total Valuation

    Enterprise value is 13.56% below the market cap, as cash exceeds debt.

    Market Cap$622.97M
    Enterprise Value$538.46M
    Latest price (Nov 17, 2026)$8.31

    Key Dates

    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 3.01% in the quarter ended Sep 30, 2026 and grew 10.65% a year over 2 years.

    Shares Outstanding63.97M
    Shares Change (YoY)+14.98%
    Shares Change (QoQ)+3.01%
    Share Count Growth (2Y CAGR)+10.65%

    Valuation Ratios

    Sales and book value multiples are 5.3x and 1.4x. Its year-end P/S ranged from 2.2x to 13.0x from 2022 to 2025.

    P/S Ratio5.3x
    Forward P/S6.9x
    P/B Ratio1.4x
    P/TBV Ratio1.5x

    Valuation history and multiples

    Price Statistics

    The stock is up 3.55% over 52 weeks and trades 19.71% below its 50-day average.

    Beta (1Y)3.31
    52-Week Change+3.55%
    1-Month Change-17.43%
    3-Month Change+7.85%
    6-Month Change+12.98%
    5-Year Change-97.97%
    Total Return (1Y)+3.55%
    Total Return (3Y CAGR)-48.47%
    Total Return (5Y CAGR)-55.57%
    Return vs SPY (1Y)-5.36%
    Max Drawdown (1Y)-48.79%
    Max Drawdown (3Y)-92.51%
    Sharpe Ratio (1Y)0.06
    Correlation with SPY (1Y)0.43
    50-Day Average$10.35
    200-Day Average$8.63
    52-Week Range$5.37 to $18.22
    RSI (14 Days)40.0
    Average Volume (20 Days)2.52M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.72x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio4.72x
    Quick Ratio4.72x
    Debt / Equity0.00x
    Interest Coverage-30.36x

    Returns and Efficiency

    Return on equity is -63.93% over the last 12 months, against a 5-year average of -92.52%.

    Return on Equity (ROE)-63.93%
    Return on Assets (ROA)-26.58%
    Return on Capital Employed (ROCE)-27.70%
    ROE (5Y Average)-92.52%
    ROA (5Y Average)-58.58%
    ROIC (5Y Average)-62.71%
    Asset Turnover0.09x
    Receivables Turnover8.22x

    Scores

    DNA has an Altman Z-Score of -9.22, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-9.22
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $100.74M over the last 12 months is down 33.11% from the 12 months before.

    Revenue$100.74M
    Revenue Growth (YoY)-33.11%
    Gross Profit$102.62M
    Operating Income-$239.49M
    Pretax Income-$255.98M
    Net Income-$251.03M
    EBITDA-$192.58M
    EBIT-$243.40M
    Reported EPS (TTM)-$4.31

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 41.57% of the $944.45M in total assets.

    Cash and Equivalents$84.50M
    Total Debt$0
    Net Cash$84.50M
    Net Cash Per Share$1.32
    Working Capital$244.99M
    Shareholder Equity$392.64M
    Book Value Per Share$6.14
    Tangible Book Value$352.91M
    Tangible Book Per Share$5.52
    Total Assets$944.45M
    Total Liabilities$551.82M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $6.56M of capital spending, operating cash flow left -$173.54M of free cash flow.

    Operating Cash Flow-$166.99M
    Capital Expenditures$6.56M
    Free Cash Flow-$173.54M
    FCF Per Share-$3.13
    Depreciation and Amortization$50.81M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -237.74%.

    Gross Margin101.87%
    Operating Margin-237.74%
    Pretax Margin-254.11%
    Net Margin-249.20%
    EBITDA Margin-191.17%
    EBIT Margin-241.62%
    FCF Margin-172.27%
    Gross Margin (5Y Average)69.44%

    Growth

    Revenue fell 29.11% a year over 3 years.

    Revenue Growth (3Y CAGR)-29.11%
    Revenue Growth (5Y CAGR)+17.29%
    Book Value Per Share Growth (2Y CAGR)-35.33%
    Tangible Book Per Share Growth (2Y CAGR)-34.78%

    Revenue and profit by year

    Dividends and Yields

    DNA does not pay a dividend. Its free cash flow yield is -32.63%.

    FCF Yield-32.63%
    Buyback Yield-2.76%
    Shareholder Yield-2.76%

    Stock Splits

    The last split was a 1-for-40 reverse split on Aug 20, 2024.

    Last Split DateAug 20, 2024
    Split TypeReverse split
    Split Ratio1:40

    Peer Position

    Against 6 similar companies, DNA has the 4th highest P/S.

    P/S Ratio5.3x vs 9.2x median
    Revenue Growth (Trailing 4 Quarters, YoY)-33.11% vs +1.89% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -24.54% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-24.54%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About DNA

    What is DNA's market cap?

    Ginkgo Bioworks Holdings has a market cap of $622.97M. Its enterprise value, which adds debt and subtracts cash, is $538.46M.

    How many shares of DNA are outstanding?

    Ginkgo Bioworks Holdings has 63.97M shares outstanding. The count is up 14.98% from a year earlier.

    Does DNA pay a dividend?

    No. Ginkgo Bioworks Holdings does not pay a dividend.

    How much debt does DNA have?

    Ginkgo Bioworks Holdings has $0 of total debt and $84.50M of cash and equivalents, a net cash position of $84.50M.